Is There a Role for Adjuvant Chemotherapy in Pathologic Node-Negative Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy?-Reference-Cited by-同舟云学术

Is There a Role for Adjuvant Chemotherapy in Pathologic Node-Negative Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy?

Published:2022-10-21 Issue:1 Volume:30 Page:224-232
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Keilson Jessica M.,Gamboa Adriana C.,Turgeon Michael K.,Maguire Lillias,Hrebinko Katherine,Holder-Murray Jennifer,Wiseman Jason T.,Ejaz Aslam,Hawkins Alexander T.,Otegbeye Ebunoluwa,Silviera Matthew,Maithel Shishir K.,Balch Glen C.

Funder

National Center for Advancing Translational Sciences of the National Institutes of Health

Abraham J. and Phyllis Katz Foundation

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-12432-0.pdf

Reference25 articles.

1. Surveillance, Epidemiology and End Results Program. SEER Cancer Statistics Review (CSR) 1975-2017. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch 2016

2. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806–15 doi: https://doi.org/10.6004/jnccn.2020.0032 [published Online First: Epub Date]|.

3. Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–53 doi: https://doi.org/10.1016/S1470-2045(14)70377-8 [published Online First: Epub Date]|.

4. Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89 doi: https://doi.org/10.1016/S1470-2045(15)00159-X [published Online First: Epub Date].

5. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010;21(9):1743–50 doi: https://doi.org/10.1093/annonc/mdq054 [published Online First: Epub Date]|.